Bitcoin halving
What does that mean?
$2.78T
Total marketcap
$104.33B
Total volume
BTC 49.64%     ETH 15.29%
Dominance

Jazz Pharmaceuticals JAZZ Stock

120.42 USD {{ price }} -0.074686% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
7.51B USD
LOW - HIGH [24H]
120.04 - 121.53 USD
VOLUME [24H]
377.65K USD
{{ volume }}
P/E Ratio
19.74
Earnings per share
6.1 USD

Jazz Pharmaceuticals Price Chart

Jazz Pharmaceuticals JAZZ Financial and Trading Overview

Jazz Pharmaceuticals stock price 120.42 USD
Previous Close 126.55 USD
Open 126.69 USD
Bid 0 USD x 800
Ask 0 USD x 800
Day's Range 126.6 - 129.07 USD
52 Week Range 124.58 - 163.31 USD
Volume 412.89K USD
Avg. Volume 489.02K USD
Market Cap 8.25B USD
Beta (5Y Monthly) 0.741197
PE Ratio (TTM) N/A
EPS (TTM) 6.1 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 200.06 USD

JAZZ Valuation Measures

Enterprise Value 12.74B USD
Trailing P/E N/A
Forward P/E 6.764428
PEG Ratio (5 yr expected) 0.61
Price/Sales (ttm) 2.20736
Price/Book (mrq) 2.473667
Enterprise Value/Revenue 3.408
Enterprise Value/EBITDA 7.59

Trading Information

Jazz Pharmaceuticals Stock Price History

Beta (5Y Monthly) 0.741197
52-Week Change -9.78%
S&P500 52-Week Change 20.43%
52 Week High 163.31 USD
52 Week Low 124.58 USD
50-Day Moving Average 135.92 USD
200-Day Moving Average 143.99 USD

JAZZ Share Statistics

Avg. Volume (3 month) 489.02K USD
Avg. Daily Volume (10-Days) 523.54K USD
Shares Outstanding 64M
Float 62.36M
Short Ratio 5.35
% Held by Insiders 2.59%
% Held by Institutions 93.06%
Shares Short 3.12M
Short % of Float 5.59%
Short % of Shares Outstanding 4.88%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -4.18%
Operating Margin (ttm) 28.66%
Gross Margin 92.40%
EBITDA Margin 44.90%

Management Effectiveness

Return on Assets (ttm) 5.87%
Return on Equity (ttm) -4.50%

Income Statement

Revenue (ttm) 3.74B USD
Revenue Per Share (ttm) 59.39 USD
Quarterly Revenue Growth (yoy) 9.70%
Gross Profit (ttm) 3.39B USD
EBITDA 1.68B USD
Net Income Avi to Common (ttm) -156287008 USD
Diluted EPS (ttm) -2.56
Quarterly Earnings Growth (yoy) 4114.89%

Balance Sheet

Total Cash (mrq) 1.17B USD
Total Cash Per Share (mrq) 18.25 USD
Total Debt (mrq) 5.81B USD
Total Debt/Equity (mrq) 174.21 USD
Current Ratio (mrq) 3.064
Book Value Per Share (mrq) 52.121

Cash Flow Statement

Operating Cash Flow (ttm) 1.38B USD
Levered Free Cash Flow (ttm) 1.42B USD

Profile of Jazz Pharmaceuticals

Country United States
State N/A
City Dublin
Address Waterloo Exchange
ZIP 4
Phone 353 1 634 7800
Website https://www.jazzpharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 2800

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Q&A For Jazz Pharmaceuticals Stock

What is a current JAZZ stock price?

Jazz Pharmaceuticals JAZZ stock price today per share is 120.42 USD.

How to purchase Jazz Pharmaceuticals stock?

You can buy JAZZ shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Jazz Pharmaceuticals?

The stock symbol or ticker of Jazz Pharmaceuticals is JAZZ.

Which industry does the Jazz Pharmaceuticals company belong to?

The Jazz Pharmaceuticals industry is Biotechnology.

How many shares does Jazz Pharmaceuticals have in circulation?

The max supply of Jazz Pharmaceuticals shares is 62.35M.

What is Jazz Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

Jazz Pharmaceuticals PE Ratio is 19.74098400 now.

What was Jazz Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

Jazz Pharmaceuticals EPS is 6.1 USD over the trailing 12 months.

Which sector does the Jazz Pharmaceuticals company belong to?

The Jazz Pharmaceuticals sector is Healthcare.

Jazz Pharmaceuticals JAZZ included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16379.46 USD
-0.12
4.79B USD 16347.38 USD 16420.92 USD 4.79B USD
NASDAQ Composite Total Return I XCMP 19904.22 USD
-0.12
19865.24 USD 19954.6 USD
NASDAQ Global Select Market Com NQGS 7966.15 USD
-0.13
7950.14 USD 7986.36 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
NYSE ARCA PHARMACEUTICAL INDEX DRG 1026.27 USD
+0.13
NASDAQ Biotechnology Total Retu XNBI 4753.69 USD
-0.36
4750.07 USD 4787.94 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1486.34 USD
+0.05
1484.78 USD 1491.97 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2657.07 USD
+0.1
2653.57 USD 2668.1 USD
Nasdaq Next Generation 100 Inde NGX 1167.15 USD
+0.03
1166.23 USD 1172.11 USD
NASDAQ Biotechnology NBI 4429.97 USD
-0.36
4426.59 USD 4461.88 USD
NASDAQ HealthCare IXHC 1011.84 USD
-0.04
1011.35 USD 1017.55 USD